2.29
4.57%
+0.10
アフターアワーズ:
2.30
0.010
+0.44%
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Hookipa Pharma (NASDAQ:HOOK) and Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Survey - Defense World
Defense World
Understanding the Risks of Investing in Corvus Pharmaceuticals Inc (CRVS) – Knox Daily - Knox Daily
Knox Daily
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Crosses Above 50-Day Moving Average of $1.77 - MarketBeat
MarketBeat
Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) market cap surged US$9.8m last week, individual investors who have a lot riding on the company were rewarded - Simply Wall St
Simply Wall St
Co-Founder Richard Miller Just Bought 8.5% More Shares In Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Yahoo News Australia
Yahoo News Australia
Corvus Pharmaceuticals director acquires $4.9m in company warrants - Investing.com
Investing.com
OrbiMed Advisors buys $4.9m in Corvus Pharmaceuticals warrants - Investing.com Nigeria
Investing.com Nigeria
Richard A. Md Miller Purchases 577634 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock - Defense World
Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) PT Raised to $8.00 at Oppenheimer - Defense World
Defense World
William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock - MarketBeat
MarketBeat
Corvus Pharmaceuticals executive buys $34,624 in company stock By Investing.com - Investing.com
Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $8.00 - MarketBeat
MarketBeat
Corvus Pharmaceuticals CEO buys $1m in company shares - Investing.com
Investing.com
Earnings call: Corvus Pharmaceuticals Q1 2024 financial results and trials update - Investing.com
Investing.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
A significant driver of top-line growth: Corvus Pharmaceuticals Inc (CRVS) – Sete News - SETE News
SETE News
William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock - MarketBeat
MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Corvus Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha
Seeking Alpha
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results - 06.05.2024 - wallstreet:online
wallstreet:online
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results | Daily - Daily Guardian Canada
Daily Guardian Canada
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire Inc.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS): It's all about numbers this morning – US Post News - US Post News
US Post News
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results - Yahoo Finance
Yahoo Finance
What Type Of Shareholders Make Up Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Share Registry? - Yahoo Movies Canada
Yahoo Movies Canada
What Type Of Shareholders Make Up Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Share Registry? - Yahoo Movies Canada
Yahoo Movies Canada
Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Monday - Defense World
Defense World
Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Monday - Defense World
Defense World
Corvus Pharmaceuticals (CRVS) to Release Earnings on Monday - MarketBeat
MarketBeat
Corvus Pharmaceuticals (CRVS) to Release Earnings on Monday - MarketBeat
MarketBeat
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 - WICZ
WICZ
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
GlobeNewswire Inc.
Corvus Pharmaceuticals raises $30.6 million in stock sale By Investing.com - Investing.com UK
Investing.com UK
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
GlobeNewswire Inc.
Corvus Pharmaceuticals raises $30.6 million in stock sale By Investing.com - Investing.com UK
Investing.com UK
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update - Defense World
Defense World
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Zacks Investment Research
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire Inc.
CRVS Stock Quote Price and Forecast - CNN
CNN
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
Zacks Investment Research
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns - TipRanks.com - TipRanks
TipRanks
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Corvus: Q4 Earnings Snapshot - Quartz
Quartz
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
GlobeNewswire Inc.
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully - Yahoo Finance
Yahoo Finance
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely? - Simply Wall St
Simply Wall St
Soquelitinib Receives FDA Orphan Drug Designation FDA for T-Cell Lymphoma - www.oncnursingnews.com/
www.oncnursingnews.com/
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Zacks Investment Research
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
GlobeNewswire Inc.
大文字化:
|
ボリューム (24 時間):